Współczesna terapia przewlekłej białaczki szpikowej

Janusz Hansz

Summary
Allogeneic hematopoietic stem cell transplantation (HSCT) with matched related or unrelated donors in chronic phase chronic myeloid leukemia (CML) is associated with long-term disease-free survival and many of such patients may be potentially curable. Treatment with interferon-alpha (IFN), alone or in combination with cytarabine in low doses improves survival, especially in patients who achieved at least major cytogenetic response. At the present time, autologous HSCT is still an experimental treatment, with long-term survival in a selected group of patients. Chemotherapy with hydroxyurea is usually applied as temporary treatment before HSCT or in combination with IFN. Newer agents such as decitabine, homoharringtonine and tyrosine kinase inhibitors are currently being investigated in clinical trials with encouraging preliminary results.

To jest tylko fragment artykułu. Aby przeczytać całość, przejdź do Czytelni medycznej.